Camurus Ab · OMXSTO:CAMX
Camurus Ab — Q2 2026 Earnings Presentation
20 slides from Camurus Ab's earnings presentation, Jul 15, 2026
Slide 1: Second quarter 2026 results
Second quarter 2026 results Audiocast presentation 15 July 2026
Slide 2: Forward looking statements
Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-look
Slide 3: Agenda
Agenda Company participants • Introduction and highlights Fredrik Tiberg, PhD President & CEO, CSO • Financial performance Anders Vadsholt • Commercial development Chief Financial Officer • R&D pipeline update Richard Jameson Chief Commercial Officer • Key take-aways • Q&A 3
Slide 4: Second quarter highlights
Second quarter highlights
Slide 5: Strong profitability and renewed commercial growth
Strong profitability and renewed commercial growth Financial & Commercial Advancing corporate execution R&D pipeline development • Total revenues SEK 702 million, • Reported Buvidal® sales SEK 524 million • CRL received for CAM2029 NDA in -+4% YoY, +32% QoQ; returned to +12% YoY, +24% OoQ acromegaly
Slide 6: Financial performance
Financial performance
Slide 7: Solid revenue growth and profitability
Solid revenue growth and profitability Revenue OPEX Operating result MSEK MSEK MSEK 800 400 400 365 702 676 330 342 292 293 600 300 300 445 400 200 200 200 100 100 83 0 0 0 Q2 2024 Q2 2025 Q2 2026 Q2 2024 Q2 2025 Q2 2026 Q2 2024 Q2 2025 Q2 2026 Buvidal sales Milestones Research and development costs
Slide 8: Further enhanced cash position
Further enhanced cash position MSEK 4 500 4 400 4 300 338 0 4 200 4 100 -104 0 4069 -41 4 000 3 900 3876 3 800 3 700 3 600 3 500 3 400 Cash Operating Operating activities ESOP Working Working Capital Investing Other Other Cash Cash end end Q1 26 Q1 2026 activities ESOP 22/26 22/26 Capital Investing
Slide 9: Capital allocation and 2026 investment priorities
Capital allocation and 2026 investment priorities •Capital allocation priorities ‒ Fund organic growth – commercial scale-up and continued R&D investment ‒ Preserve balance sheet strength and flexibility ‒ Continue business development – partnerships and new opportunities •2026 investment priorities
Slide 10: Commercial development
Commercial development
Slide 11: Buvidal – strong sales growth
Buvidal – strong sales growth •Record quarterly sales, exceeding SEK 500 million • Est. number of patients in treatment with Buvidal ‒ Q2 2026 net sales of SEK 524 million (470), +12% YoY (+11% CER) 80,000 77,000 • +24% vs the previous quarter (+21% CER) • In-market growth of +19% vs Q2 2025 and +6%
Slide 12: Brixadi market performance in the US
Brixadi market performance in the US •Strong Q2 rebound Brixadi royalty by quarter ‒ Royalty in Q2 SEK 127 million (89), +42% (+37% CER) YoY, MSEK +20% (+14% CER) QoQ – highest quarter to date 140 127 ‒ Estimated equivalent unit volume up ~15% versus Q1 2026 122 120 111 •Brixadi growth on expanding
Slide 13: Oczyesa launch momentum in Europe
Oczyesa launch momentum in Europe •Sales in Germany continued according to plan Oczyesa wave 1 countries in acromegaly ‒ Second quarter sales of SEK 4 million ‒ Continued positive patient and physician feedback ‒ Focus for H2: broaden adoption toward a double-digit share of SRL-treated acromegaly pa
Slide 14: R&D pipeline update
R&D pipeline update
Slide 15: CAM2029 status and progress in Q2 2026
CAM2029 status and progress in Q2 2026 Acromegaly GEP-NET PLD Pivotal randomized placebo controlled Subcutaneous Octreotide Randomized Polycystic liver Safety and efficacy and long-term safety trials in acromegaly Efficacy in Neuroendocrine TumOrs TriAl with subcutaneous Octreotide ACROINNOVA Phase
Slide 16: CAM2056 and early R&D programs
CAM2056 and early R&D programs CAM2056 Early-stage partner programs Positive Phase 1b data Long-acting incretins with Eli Lilly announced in Nov 2025 Partnership entered Jun 2025 Type B meeting with the FDA Covers dual GLP-1/GIP and triple Completion of regulatory GLP-1/GIP/glucagon agonists with Fl
Slide 17: Strategic priorities going forward
Strategic priorities going forward
Slide 18: Clear path to continued value creation
Clear path to continued value creation Commercial execution Advancing pipeline Partnerships and M&A excellence with high potential opportunities • Strengthen market leadership • SORENTO readout in GEP-NET • Progressing partnerships with in opioid dependence treatment • Start of Phase 2b for CAM2056
Slide 19: Q&A
Q&A Camurus AB│Rydbergs torg 4, SE-224 84 Lund, Sweden P +46 46 286 57 30│info@camurus.com│camurus.com
Slide 20: Shareholders and analyst coverage
Shareholders and analyst coverage Shareholders as of 30 June Number of shares % of capital % of votes Sandberg Development AB 18,280,692 30.2 30.2 Analysts Fourth Swedish National Pension Fund 2,729,277 4.5 4.5 DNB Carnegie Handelsbanken fonder 1,713,314 2.8 2.8 Erik Hultgård Handelsbanken Vanguard